Characterization of MHC ligands for peptide based tumor vaccination

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3221-3236

  Klug, Felix ^a   Miller, Matthias ^a   Schmidt, Hans Henning ^a   Stevanović, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Anchor residues; Epitope prediction; HLA ligandome; Major histocompatibility complex; Mass spectrometry; Peptide motifs; Phosphorylation; Stable isotope labelling

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N HYDROXYSUCCINIMIDE; NICOTINOYLOXYSUCCINIMIDE D 4; NICOTINOYLOXYSUCCINIMIDE H 4; PEPTIDE VACCINE; PROTEASOME; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EPITOPE MAPPING; HUMAN; IMMUNOPRECIPITATION; ISOTOPE LABELING; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; T LYMPHOCYTE ACTIVATION; TANDEM MASS SPECTROMETRY;

ANIMALS; CANCER VACCINES; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; GENES, MHC CLASS I; GENES, MHC CLASS II; HLA ANTIGENS; HUMANS; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN CONFORMATION; VACCINES, SUBUNIT;

EID: 70449434636     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105180     Document Type: Review

References (132)

1. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-512 (Pubitemid 17131093)
2. Wilson IA, Fremont DH. Structural analysis of MHC class I molecules with bound peptide antigens. Semin Immunol 1993; 5: 75-80.
3. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994; 265: 398-402. (Pubitemid 24259973)
4. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
5. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929-937 (Pubitemid 23270612)
6. Matsumura M, Saito Y, Jackson MR, Song ES, Peterson PA. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J Biol Chem 1992; 267: 23589-23595
7. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992; 257: 919-927
8. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994; 371: 626-629
9. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156: 3308-3314
10. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-5592 (Pubitemid 24377694)
11. Silver ML, Guo HC, Strominger JL, Wiley DC. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature 1992; 360: 367-369
12. Madden DR, Gorga JC, Strominger JL, Wiley DC. The threedimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70: 1035-1048
13. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992; 257: 927-934
14. Moll A, Hildebrandt A, Lenhof HP, Kohlbacher O. BALLView: an object-oriented molecular visualization and modeling framework. J Comput Aided Mol Des 2005; 19: 791-800. (Pubitemid 43298658)
15. Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002; 39: 147-164 (Pubitemid 35013508)
16. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003; 3: 472-482 (Pubitemid 37339187)
17. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028. (Pubitemid 40563191)
18. Ackerman AL, Cresswell P. Cellular mechanisms governing crosspresentation of exogenous antigens. Nat Immunol 2004; 5: 678-684 (Pubitemid 39023296)
19. Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006; 25: 607-617 (Pubitemid 44529035)
20. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005; 207: 145-157 (Pubitemid 41415014)
21. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA 2005; 102: 7922-7927 (Pubitemid 40781039)
22. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, et al. Major histocompatibility complex class IIrestricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33: 1250-1259 (Pubitemid 36609143)
23. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007; 26: 79-92. (Pubitemid 46109341)
24. Strawbridge AB, Blum JS. Autophagy in MHC class II antigen processing. Curr Opin Immunol 2007; 19: 87-92.
25. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigenpresenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007; 7: 543-555 (Pubitemid 46987783)
26. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404: 770-774 (Pubitemid 30212405)
27. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 2001; 114: 845-851 (Pubitemid 32266257)
28. Stoltze L, Schirle M, Schwarz G, Schroter C, Thompson MW, Hersh LB, et al. Two new proteases in the MHC class I processing pathway. Nat Immunol 2000; 1: 413-418
29. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5: 670-677 (Pubitemid 39023295)
30. Hammer GE, Gonzalez F, James E, Nolla H, Shastri N. In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol 2007; 8: 101-108
31. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002; 419: 480-483
32. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-296 (Pubitemid 21896578)
33. Rudensky A, Beers C. Lysosomal cysteine proteases and antigen presentation. Ernst Schering Res Found Workshop 2006: 81-95.
34. Chapman HA. Endosomal proteases in antigen presentation. Curr Opin Immunol 2006; 18: 78-84.
35. Watts C, Moss CX, Mazzeo D, West MA, Matthews SP, Li DN, et al. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann N Y Acad Sci 2003; 987: 9-14.
36. Hastings KT, Lackman RL, Cresswell P. Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing. J Immunol 2006; 177: 8569-8577 (Pubitemid 44893819)
37. Godkin AJ, Smith KJ, Willis A, Tejada-Simon MV, Zhang J, Elliott T, et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide- MHC interactions. J Immunol 2001; 166: 6720-6727 (Pubitemid 32467215)
38. Kropshofer H, Max H, Halder T, Kalbus M, Muller CA, Kalbacher H. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. J Immunol 1993; 151: 4732-4742 (Pubitemid 23318526)
39. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
40. Purcell AW, Gorman JJ. Immunoproteomics: mass spectrometrybased methods to study the targets of the immune response. Mol Cell Proteomics 2004; 3: 193-208.
41. Storkus WJ, Zeh HJ, 3rd, Salter RD, Lotze MT. Identification of Tcell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol 1993; 14: 94-103.
42. Fortier MH, Caron E, Hardy MP, Voisin G, Lemieux S, Perreault C, et al. The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 2008; 205: 595-610.
43. Torabi-Pour N, Nouri AM, Saffie R, Oliver RT. Comparative study between direct mild acid extraction and immunobead purification technique for isolation of HLA class I-associated peptides. Urol Int 2002; 68: 38-43. (Pubitemid 34102570)
44. Van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990; 348: 213-216 (Pubitemid 20383086)
45. Yu YQ, Gilar M, Lee PJ, Bouvier ES, Gebler JC. Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. Anal Chem 2003; 75: 6023-6028 (Pubitemid 37356487)
46. Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W. Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 1997; 45: 379-385 (Pubitemid 27163177)
47. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62: 5818-5827 (Pubitemid 35204741)
48. Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005; 54: 826-836 (Pubitemid 40991325)
49. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, Rammensee HG. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 1991; 174: 425-434
50. Edman P. A method for the determination of amino acid sequence in peptides. Arch Biochem 1949; 22: 475.
51. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255: 1261-1263
52. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev 2001; 101: 269-295
53. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, Paharkova-Vatchkova V, et al. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol 2001; 31: 1485-1494
54. Hickman HD, Luis AD, Buchli R, Few SR, Sathiamurthy M, VanGundy RS, et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 2004; 172: 2944-2952 (Pubitemid 38263681)
55. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64-71. (Pubitemid 19252085)
56. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410 (Pubitemid 20364473)
57. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11: 213-244 (Pubitemid 23115007)
58. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999; 17: 676-682 (Pubitemid 29316146)
59. Washburn MP, Wolters D, Yates JR, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242-247
60. Stevanovic S, Schild H. Quantitative aspects of T cell activation-- peptide generation and editing by MHC class I molecules. Semin Immunol 1999; 11: 375-384 (Pubitemid 30047499)
61. "SYFPEITHI, a database of MHC ligands and peptide motifs.". from www.syfpeithi.de.
62. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219 (Pubitemid 30099526)
63. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000; 30: 2216-2225 (Pubitemid 30655761)
64. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 2001; 61: 4072-4077 (Pubitemid 32720973)
65. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988; 110: 29-36.
66. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159: 197-207. (Pubitemid 23071909)
67. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96
68. Dimopoulos N, Jackson HM, Ebert L, Guillaume P, Luescher IF, Ritter G, et al. Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells. J Immunol Methods 2009; 340: 90-94
69. Weinzierl AO, Stevanović S. LC-MS based protein and peptide quantification using stable isotope labels: from ICAT in general to differential N-terminal coding (dNIC) in special. Genet Eng Rev 2006; 23.
70. Putz S, Reinders J, Reinders Y, Sickmann A. Mass spectrometrybased peptide quantification: applications and limitations. Expert Rev Proteomics 2005; 2: 381-392 (Pubitemid 40839748)
71. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007; 389: 1017-1031 (Pubitemid 47482251)
72. Gevaert K, Impens F, Ghesquiere B, Van Damme P, Lambrechts A, Vandekerckhove J. Stable isotopic labeling in proteomics. Proteomics 2008; 8: 4873-4885
73. Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 2004; 22: 450-454 (Pubitemid 38451377)
74. Munchbach M, Quadroni M, Miotto G, James P. Quantitation and facilitated de novo sequencing of proteins by isotopic N-terminal labeling of peptides with a fragmentation-directing moiety. Anal Chem 2000; 72: 4047-4057 (Pubitemid 30694753)
75. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005; 5: 4-15. (Pubitemid 40189632)
76. Bondarenko PV, Chelius D, Shaler TA. Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. Anal Chem 2002; 74: 4741-4749 (Pubitemid 35051732)
77. Mason DE, Liebler DC. Quantitative analysis of modified proteins by LC-MS/MS of peptides labeled with phenyl isocyanate. J Proteome Res 2003; 2: 265-272
78. Cagney G, Emili A. De novo peptide sequencing and quantitative profiling of complex protein mixtures using mass-coded abundance tagging. Nat Biotechnol 2002; 20: 163-170
79. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotopecoded affinity tags. Nat Biotechnol 1999; 17: 994-999 (Pubitemid 29474856)
80. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005; 1: 252-262
81. Keough T, Lacey MP, Youngquist RS. Derivatization procedures to facilitate de novo sequencing of lysine-terminated tryptic peptides using postsource decay matrix-assisted laser desorption/ ionization mass spectrometry. Rapid Commun Mass Spectrom 2000; 14: 2348-2356 (Pubitemid 32001088)
82. Brancia FL, Butt A, Beynon RJ, Hubbard SJ, Gaskell SJ, Oliver SG. A combination of chemical derivatisation and improved bioinformatic tools optimises protein identification for proteomics. Electrophoresis 2001; 22: 552-559 (Pubitemid 32166580)
83. Beardsley RL, Reilly JP. Optimization of guanidination procedures for MALDI mass mapping. Anal Chem 2002; 74: 1884-1890
84. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 2002; 188: 164-176 (Pubitemid 35398874)
85. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003; 100: 6940-6945 (Pubitemid 36706372)
86. Desiderio DM, Kai M. Preparation of stable isotope-incorporated peptide internal standards for field desorption mass spectrometry quantification of peptides in biologic tissue. Biomed Mass Spectrom 1983; 10: 471-479
87. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-1169
88. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, et al. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007; 7: 3651-3660 (Pubitemid 350022271)
89. Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res 2005; 4: 1442-1450 (Pubitemid 41208703)
90. Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE. Labelfree LC-MS method for the identification of biomarkers. Methods Mol Biol 2008; 428: 209-230
91. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem 2004; 76: 6085-6096
92. Liu H, Sadygov RG, Yates JR, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76: 4193-4201
93. Marsh SG. Nomenclature for factors of the HLA system, update October 2008. Hum Immunol 2009.
94. Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996; 17: 261-266 (Pubitemid 26183489)
95. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9: 1.
96. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62: 1009-1030 (Pubitemid 32835065)
97. Hillen N, Mester G, Lemmel C, Weinzierl AO, Muller M, Wernet D, et al. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur J Immunol 2008; 38: 2993-3003.
98. Schuler MM, Nastke MD, Stevanovikc S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 2007; 409: 75-93.
99. Yague J, Alvarez I, Rognan D, Ramos M, Vazquez J, de Castro JA. An N-acetylated natural ligand of human histocompatibility leukocyte antigen (HLA)-B39. Classical major histocompatibility complex class I proteins bind peptides with a blocked NH(2) terminus in vivo. J Exp Med 2000; 191: 2083-2092 (Pubitemid 30416355)
100. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000; 192: 1755-1762 (Pubitemid 32049768)
101. Xu Y, Gendler SJ, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 2004; 199: 707-716 (Pubitemid 38316437)
102. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986; 324: 258-260
103. Dengjel J, Rammensee HG, Stevanovic S. Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom 2005; 40: 100-104 (Pubitemid 40188986)
104. Wu HY, Liao PC. Analysis of protein phosphorylation using mass spectrometry. Chang Gung Med J 2008; 31: 217-227 (Pubitemid 351841541)
105. Hillen N, Stevanovic S. Contribution of mass spectrometry-based proteomics to immunology. Expert Rev Proteomics 2006; 3: 653-664 (Pubitemid 46021201)
106. Reinders J, Lewandrowski U, Moebius J, Wagner Y, Sickmann A. Challenges in mass spectrometry-based proteomics. Proteomics 2004; 4: 3686-3703
107. Schuler MM, Donnes P, Nastke MD, Kohlbacher O, Rammensee HG, Stevanovic S. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 2005; 57: 816-820 (Pubitemid 41817939)
108. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHCbinding epitopes. Curr Opin Immunol 2006; 18: 92-97 (Pubitemid 43049654)
109. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004; 427: 252-256 (Pubitemid 38112041)
110. van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006; 18: 98-104. (Pubitemid 43049655)
111. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304: 587-590 (Pubitemid 38541917)
112. Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A, et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006; 313: 1444-1447 (Pubitemid 44360274)
113. Altrich-VanLith ML, Ostankovitch M, Polefrone JM, Mosse CA, Shabanowitz J, Hunt DF, et al. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol 2006; 177: 5440-5450 (Pubitemid 44527617)
114. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritisassociated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-541 (Pubitemid 36871358)
115. Qiao SW, Bergseng E, Molberg O, Jung G, Fleckenstein B, Sollid LM. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J Immunol 2005; 175: 254-261 (Pubitemid 40884326)
116. Qiao SW, Bergseng E, Molberg O, Xia J, Fleckenstein B, Khosla C, et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 2004; 173: 1757-1762 (Pubitemid 38971607)
117. Mohammed F, Cobbold M, Zarling AL, Salim M, Barrett-Wilt GA, Shabanowitz J, et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol 2008; 9: 1236-1243
118. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999; 163: 3812-3818 (Pubitemid 29450906)
119. Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, Lewis ST, et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci USA 2006; 103: 14889-14894 (Pubitemid 44527824)
120. Depontieu F, Qian J, Zarling AL, McMiller TL, Shabanowitz J, Hunt DF, et al. Tumor-associated MHC II-restricted phosphopeptides: New targets for immune recognition. FASEB J 2008; 22: 1079.1.
121. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-1457
122. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647 (Pubitemid 21917508)
123. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854 (Pubitemid 35231542)
124. Kolb HJ, Simoes B, Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 2004; 16: 167-173 (Pubitemid 38402532)
125. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129
126. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 21: 1859-1874 (Pubitemid 47299958)
127. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
128. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 184-190
129. Slingluff CL, Jr., Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48: 661-672 (Pubitemid 30146461)
130. Mouhat S, Andreotti N, Jouirou B, Sabatier JM. Animal toxins acting on voltage-gated potassium channels. Curr Pharm Des 2008; 14(24): 2503-2518
131. Norton RS, McDonough SI. Peptides targeting voltage-gated calcium channels. Curr Pharm Des 2008; 14(24): 2480-2491
132. van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008; 14(28): 2914-2931